'Goldilocks' drug prevents chronic kidney disease in primates

January 10, 2017, Massachusetts General Hospital
This image shows a cross section of a kidney. Credit: Holly Fischer/Wikipedia

Cells in any organ will die if their blood supply is cut off - such as during a heart attack, stroke, or organ transplant - but restoring circulation can also cause damage. Now a Massachusetts General Hospital (MGH) research team, using the kidney as an example, has developed a way to avoid this so-called ischemia/reperfusion injury with a new monoclonal antibody that binds its target in a way that is "just right." They describe their work in the online journal Nature Communications.

"Ischemia/reperfusion injury is the leading cause of , which is a strong predictor of in humans and a growing health care burden," says M. Amin Arnaout, MD, chief emeritus of the Division of Nephrology at MGH and senior author of the study. "Ischemia/reperfusion injury is also a major cause of delayed graft function and transplant rejection, not just in kidneys but in other organs as well. Over the years we've learned that the problem is inflammation - which is caused by the white blood cells called leukocytes - so we set out to block those cells in a way that prevents ischemia/reperfusion injury while avoiding inadvertent side effects." Arnaout directs both the Leukocyte Biology Program and the Inflammation and Structural Biology Program at MGH.

Leukocytes respond to tissue by causing inflammation. If damage is mild, inflammation is limited and can be beneficial, helping cells and tissues to heal. However, if damage is serious or takes place in tissue that is already diseased, inflammation can run rampant and cause further damage, impairing organ function or leading to rejection of a transplanted organ. Ischemia/reperfusion injury induces the release of pro-inflammatory molecules that attract leukocytes, which then release more pro-inflammatory molecules in a vicious cycle that can lead to the loss of the organ.

Previous attempts to suppress ischemia/reperfusion injury by targeting these pro-inflammatory molecules seemed to work in mouse models but failed in humans. The reason, Arnaout's team suspected, has to do with the biology of how leukocytes signal to propagate tissue damage. The majority of inflammatory leukocytes that enter an ischemic organ after reperfusion communicate via a receptor molecule called CD11b/CD18, one of a group of membrane proteins called integrins. The signaling role of CD11b/CD18 has made this receptor a tempting target for drug development, particularly the use of antibodies that specifically bind to the receptor and block its function. However, in previous attempts using mouse models, antibodies that bound to CD11b/CD18 could inadvertently activate it, triggering the very damage they were supposed to prevent. Arnaout says, "Just like Goldilocks wanted a chair that wasn't too soft or too hard, we needed to find an antibody that bound enough to block receptor function but not enough to activate it."

Arnaout's research has focused on how the structure of integrins affects their signaling function, and his team was the first to describe how integrins change their shape when they are activated. To hit the "sweet spot" by blocking CD11b/CD18 on inflammatory leukocytes without activating the receptor, the team developed a new monoclonal antibody called mAb107. To get a better idea of whether mAb107 might prevent kidney damage following severe ischemia/reperfusion injury in humans, they tested it in cynomolgus monkeys instead of mice. The team's experiments showed that administering mAb107 at the outset and during ischemia/reperfusion injury of the monkeys' kidneys halted fibrotic kidney failure, which was otherwise irreversible in an untreated control group. The use of mAb107 successfully blocked the site where pro-inflammatory molecules bind to CD11b/CD18 without activating the receptor.

"The mechanisms underlying ischemia/reperfusion injury in the kidney are similar to those in the heart and brain, so we think mAb107 could also be useful in treating and stroke," says Arnaout, who is a professor of Medicine at Harvard Medical School. "Furthermore, because ischemia/reperfusion injury affects organ transplants, treating organ donors and/or recipients with a humanized version of mAb107 could have widespread benefit for the 30,000 patients who receive transplants each year." Arnaout's team is now investigating in animal models the use of mAb107 to block ischemia/reperfusion in kidney transplants and evaluating its ability to reduce heart failure after a major heart attack.

Explore further: Statin rx may prevent myocardial ischemia-reperfusion injury

More information: Nature Communications, DOI: 10.1038/NCOMMS13899

Related Stories

Statin rx may prevent myocardial ischemia-reperfusion injury

September 12, 2016
(HealthDay)—Postconditioning with rosuvastatin prevents myocardial ischemia-reperfusion injury in a rat model, according to a study published online Aug. 31 in Cardiovascular Therapeutics.

New study shows intravenous glutamine reduces ischemia reperfusion injuries

June 9, 2015
A single dose of intravenous glutamine (GLN) administered immediately after a non-lethal lower limb ischemia reduces the reperfusion inflammatory reaction locally and systemically according to a new study.

Researchers find females more resistant to organ damage following kidney transplant

April 18, 2016
After a kidney transplant, women may experience decreased kidney damage from ischemia reperfusion injury compared to men due to the impact of gender-specific hormones, suggests a new preclinical study and an analysis of patient ...

BAG3 protein plays critical role in protecting heart from reperfusion injury, research shows

November 17, 2016
The inability of cells to eliminate damaged proteins and organelles following the blockage of a coronary artery and its subsequent re-opening with angioplasty or medications - a sequence known as ischemia/reperfusion - often ...

Olive oil component alleviates intestinal ischemia and reperfusion

February 5, 2013
Here's another reason why you should include olive oil in your diet: A new research report published in the Journal of Leukocyte Biology suggests that at least one compound in olive oil significantly reduces intestinal ischemia ...

Renal dopamine signaling prevents kidney injury and improves blood pressure in mice

June 2, 2016
Dopamine signaling in the kidneys plays a critical role in blood pressure regulation and is responsible for nearly half of the salt and water excretion that occurs in response to increased dietary salt intake. Notably, genetic ...

Recommended for you

Clues to obesity's roots found in brain's quality control process

February 20, 2018
Deep in the middle of our heads lies a tiny nub of nerve cells that play a key role in how hungry we feel, how much we eat, and how much weight we gain.

Study looks at how newly discovered gene helps grow blood vessels

February 19, 2018
A new study published today found that a newly discovered gene helps grow blood vessels when it senses inadequate blood flow to tissues.

Scientists produce human intestinal lining that re-creates living tissue inside organ-chip

February 16, 2018
Investigators have demonstrated how cells of a human intestinal lining created outside an individual's body mirror living tissue when placed inside microengineered Intestine-Chips, opening the door to personalized testing ...

Data wave hits health care

February 16, 2018
Technology used by Facebook, Google and Amazon to turn spoken language into text, recognize faces and target advertising could help doctors fight one of the deadliest infections in American hospitals.

Researcher explains how statistics, neuroscience improve anesthesiology

February 16, 2018
It's intuitive that anesthesia operates in the brain, but the standard protocol among anesthesiologists when monitoring and dosing patients during surgery is to rely on indirect signs of arousal like movement, and changes ...

Team reports progress in pursuit of sickle cell cure

February 16, 2018
Scientists have successfully used gene editing to repair 20 to 40 percent of stem and progenitor cells taken from the peripheral blood of patients with sickle cell disease, according to Rice University bioengineer Gang Bao.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.